NCT07636967 Isokinetic Profile of Ankle Joint Muscles in Chronic Non Specific Low Back Pain Patients
| NCT ID | NCT07636967 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Chronic Non-specific Low Back Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-06-13 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-06-13 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic non-specific low back pain and its resulting infirmity have become a huge health and socioeconomic burden. Low back pain is reportedly associated with decreased activities of daily living and quality of life. Previous literature supports the presence of a link between CLBP and lower limb kinematics that can contribute to functional limitations and disability. For example, CLBP commonly coexist with postural and structural asymmetry. Ankle muscle performance of individuals with LBP during gait becomes more clinically important as it may provide insights into the mechanisms of ankle strategies. The isokinetic testing is an assessment method of high effectivity and trustworthiness that can be used to compare bilateral and agonist/ antagonist ankle muscles strength of normal subjects and athletes. It can be used to analyze muscular performance and differences in muscle performance between dominant and non-dominant limbs.
Eligibility Criteria
Inclusion Criteria: 1. 50 male patients diagnosed with Chronic non-specific low back pain through direct referral from their orthopedic surgeon. 2. Each patient will be diagnosed by "Waddle sign" 3. Age limit 20-40 years. 4. BMI: less than 30. 5. Pain duration: chronic more than 3 months or 12 weeks. 6. Pain location: Between T12- and lower gluteal folds. 7. Pain Intensity: At least have 3 out of 10 on VAS. 8. Level of functional disability: 21%-40% on MODI. 9. Each patient sign an informed consent. Exclusion Criteria: 1. Unexplained weight loss. 2. History of malignancy. 3. Recent trauma within last 12 months. 4. Osteoporosis. 5. Cauda Equina Symptoms. 6. Herniated discs. 7. Radicular signs. 8. Spine fractures. 9. Spinal Canal Stenosis. 10. Myofascial Pain Syndrome. 11. Spondylolisthesis. 12. Rheumatological history. 13. CVS manifestations. 14. GIT manifestations. 15. Psychiatric disorders. 16. Weakness or parathesis in L.L. 17. History of back surgery. 18. Chronic Ankle Instability. 19. Scoliosis or leg length discrepancies. 20. Neurological and systemic manifestations such Epilepsy, muscular diseases, or seziures. 21. Mechanical back pain
Contact & Investigator
Mohamed Hazem Abdelhakam Elshafey, Demonstrator (TA)
✉ mohamedhazem3333333333@gmail.com📞 +201114946552
Maha Mostafa Alibeiny, Associate Professor
STUDY DIRECTOR
Cairo University
Frequently Asked Questions
Who can join the NCT07636967 clinical trial?
This trial is open to male participants only, aged 20 Years or older, up to 40 Years, studying Chronic Non-specific Low Back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07636967 currently recruiting?
Yes, NCT07636967 is actively recruiting participants. Contact the research team at mohamedhazem3333333333@gmail.com for enrollment information.
Where is the NCT07636967 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07636967 clinical trial?
NCT07636967 is sponsored by Cairo University. The principal investigator is Maha Mostafa Alibeiny, Associate Professor at Cairo University. The trial plans to enroll 50 participants.